Additional Warrant. As additional consideration for Warrantholder’s exercise of the Warrant in accordance with the terms of the Warrant and this Amendment, the Corporation hereby issues to Warrantholder a warrant to purchase sixty-two thousand five hundred (62,500) shares Common Stock substantially in the form attached hereto as Exhibit A (the “Additional Warrant”).
Additional Warrant. If on or before February 28, 2016, the ACF Indebtedness has not been repaid in full, the liens securing such ACF Indebtedness have not been released, and the ACF Loan Documents have not been terminated, then Borrower shall issue to Agent an additional warrant for stock in Borrower valued, at the time of such issuance, at $1,250,000, the form and the terms of which shall be substantially similar to the form and terms of the Closing Date Warrant or as otherwise agreed to by Agent and Borrower.
Additional Warrant. (i) Subject to the provisions of this Section, on February 28, 2008, Vemics will issue to EL Desktop an additional warrant for 750,000 restricted shares of Vemics Common Stock, with a strike price equal to 90% of the average of the closing prices of Vemics Common Stock over the 30 trading days immediately preceding February 28, 2008 (as reported in the pink sheets or, if Vemics Common Stock is traded on an exchange, as reported by such exchange) (if Vemics Common Stock is not traded in the pink sheets or on an exchange an any date during said 30 trading days, a share of Vemics Common Stock shall be valued at US$.90 so that the strike price would be US$.81), if the amount of net revenue received by Verities which is generated by Xxxxxxxxxx as an employee of Vemics between the Closing Date and February 28, 2008, is US$2,250,000 or more. If Vemics does, or is obligated to, issue such an additional warrant to EL Desktop pursuant to this Section 2(b)(2)(i), then no additional warrant shall be issued or issuable pursuant to Section 2(b)(2)(ii).
Additional Warrant. Upon the earlier of (i) the Next Round Financing or (ii) June 30, 2010, Borrower shall issue Lender the Additional Warrant to purchase such number of shares of Borrower’s Preferred Stock equal to 3% of the Advances drawn hereunder divided by the applicable Exercise Price. In the event that a Next Round Financing under subsection (i) of the definition of the Next Round Financing set forth above is completed on or before June 30, 2010, the Additional Warrant shall be exercisable for the preferred stock issued in such Next Round Financing at the Exercise price equal to the Price per share of Borrower’s preferred stock paid by investors in the Next Round Financing. In the event the Next Round Financing under subsection (ii) of the definition of the Next Round Financing set forth above is completed on or before June 30, 2010 (provided that a Next Round Financing under subsection (i) of the definition of the Next Round Financing has not been previously completed) or if a Next Round Financing under subsection (i) of the definition of the Next Round Financing set forth above is not completed on or before June 30, 2010, then the Additional Warrant shall be exercisable to purchase shares of Borrower’s Series A-1 Preferred Stock with an Exercise Price equal to the Series A-1 Price. Notwithstanding the foregoing, if the Next Round Financing as defined within subsection (i) of the definition of the Next Round Financing with respect to the authorization and issuance of a new series of Preferred Stock shall occur prior to the Commitment Termination Date, the Additional Warrant shall be issued in accordance with the terms hereof within 3 days following the Commitment Termination Date.
Additional Warrant. MICA hereby agrees that, no later than three business days after the date of this Agreement, MICA shall issue and deliver to GE Medical a Common Stock Purchase Warrant (the "Additional Warrant"), in the form attached hereto as Exhibit A, to purchase 60,000 fully paid and nonassessable Common Shares, at an exercise price of $8.50 per Common Share, which exercise price shall be adjusted as set forth in the Additional Warrant. The Additional Warrant shall be executed on behalf of MICA by the president or any executive officer of MICA under its corporate seal.
Additional Warrant. Upon the First Commercial Introduction, Licensee shall promptly grant and deliver (within thirty (30) days of the First Commercial Introduction) to Medtronic or to a subsidiary designated by Medtronic, as an additional royalty payment, an additional warrant (the "Additional Warrant"), in the form attached as Exhibit C, except that: (i) the Additional Warrant shall entitle the holder to purchase 223,777 shares of common stock of Licensee, which Licensee represents is equal to 2.5% (two and one-half percent) of the total issued and outstanding common stock of Licensee as of the Effective Date; (ii) the per share exercise price of such Additional Warrant shall be equal to: (A) 1.25 (one and one-quarter) times the average closing price of Licensee's common stock for the twenty (20) trading days ending on and including the trading day immediately preceding the date of the First Commercial Introduction, in the event the Additional Warrant is being issued because of the First Commercial Introduction, (B) the average closing price of Licensee's common stock for the twenty (20) trading days ending on and including the trading day immediately preceding the date of the announcement of the proposed Change of Control, in the event the Additional Warrant is being issued because of a Change of Control as provided in clause (iv) below, and (C) 1.25 (one and one-quarter) times the average closing price of Licensee's common stock for the twenty (20) trading days ending on and including the trading day immediately preceding the 24-month anniversary date of the execution of this Agreement, in the event the Additional Warrant is being issued prior to the First Commercial Introduction as provided in the last sentence of this Section 3.3; (iii) the Additional Warrant shall not become exercisable (except in the event of a Change of Control of Licensee, as defined in Section 2.6) until the one-year anniversary of the Additional Warrant's issuance and shall expire five (5) years from the date of the Additional Warrant's issuance; and (iv) notwithstanding anything herein to the contrary, the Additional Warrant shall, if not already issued, be issued immediately prior to any Change of Control of Licensee and, shall, by its terms, automatically become exercisable immediately prior to any Change of Control of Licensee. Furthermore, if the First Commercial Introduction has not occurred by the twenty-four (24) month anniversary of the execution of this Agreement, then the Licensee shall ...
Additional Warrant. In addition to the Warrant specified in Article 4.A above, subject to CERES’ Board of Directors and shareholder approval, Articles 1.A.(2), 4.C, 4.D and 4.E and agreement by the Parties on the terms and conditions of the warrants, CERES shall issue to SYSTEM a warrant to purchase up to two hundred thousand (200,000) shares of CERES’ Common Stock (the “Additional Warrant”) at a defined price. The maximum duration of the Additional Warrant would be fifteen (15) years; early termination provisions may apply. The Additional Warrant would become exercisable in installments as follows, provided that, at the time of SYSTEM’s exercise of such installment, (i) SYSTEM has not breached, and is not in breach of any provision of the ARSRA, this Agreement (including without limitation the Guidelines), Existing Licenses and Material Transfer Agreements (as defined in the ARSRA), or any license entered into pursuant to this Agreement, (ii) SYSTEM has not proceeded to any activities (including participation in any Additional Collaboration Project and/or use of any Lines, Hybrids, Derivatives or Progeny developed in the Program) contrary to CERES’ expressed preference, as referred to in clause 1.2 of the Guidelines, and (iii) SYSTEM has not collaborated or is not collaborating with, nor has granted rights to, any party for Germplasm Improvement (as defined in the ARSRA) of Biomass/Bioenergy/Sweet Sorghum (as defined in the ARSRA) except as expressly permitted in the ARSRA;
Additional Warrant. If all principal, interest and other amounts under the Loans and the Note have not been paid in full and Lender's obligation to make Loans has not been terminated on or prior to the second anniversary following the first funding hereunder, Borrower shall issue to Lender a warrant ("Additional Warrant") to purchase a number of shares of Borrower's Common Stock equal to 7,500,000 multiplied by a fraction, the numerator of which shall be the principal amount of the Loans outstanding on such second anniversary and the denominator of which shall be $10.0 million. The number of shares subject to such Additional Warrant shall be subject to appropriate adjustment if any of the events described in Sections 5.1, 5.2, 5.3, 5.5 and 5.9 of the Warrant attached as Exhibit B-1 occurs prior to such second anniversary. The exercise price of such Additional Warrant shall be $0.10 per share. The Additional Warrant shall expire seven years following the date of issuance. The Additional Warrant shall be substantially identical to the Warrant attached as Exhibit B-1 (except that the antidilution adjustments will be appropriately modified so as to adjust the number of shares only and the number of shares subject to the Additional Warrant shall be reduced as set forth in Sections 5.1, 5.2, 5.3, 5.5 and 5.9 of the Warrant).
Additional Warrant. Issuer shall issue to Holder a stock purchase warrant allowing for the purchase of 330,882 shares of common stock (calculated by dividing the product of the principal amount and .75 by .17), at $0.25 per share, for a period of five years (expiring August 16, 2024). The warrant allows for cashless exercise only after 18 months and provided that the shares underlying the warrant are not registered with the SEC. Once the shares are registered, cash is required to exercise the warrant.
Additional Warrant. The Investors will receive a warrant to purchase additional shares of Convertible Preferred Stock at the same per share price of the Convertible Preferred Stock issuable upon conversion of the Notes, which shall be exercisable for a period of three (3) months following the closing of the effectiveness of the Registration Statement described below. The warrant shall provide for the purchase of up to an aggregate maximum of US$5,000,000 in Surviving Company Shares and Surviving Company Warrants (the warrant will be subject to such customary additional terms not inconsistent with the below):
